D. Janson

The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine

P. Wang, R. Gartenhaus, M. Hoffman, 1996, Journal of Molecular Medicine.

Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.

M. Hoffman, D. Janson, K. Rai, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical staging and prognostic markers in chronic lymphocytic leukemia.

K. Rai, B. Mehrotra, T. Wasil, 2004, Hematology/oncology clinics of North America.

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.

L. Gordon, M. Tallman, T. Kuzel, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

N Gupta, S Kavuru, D Patel, 2002, Leukemia.

Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia

K. Rai, T. Wasil, N. Kohn, 2011, Medical oncology.

Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2'-deoxyadenosine: implications for susceptibility to opportunistic infections.

P. Fitzgerald-Bocarsly, F. Siegal, A. Sawitsky, 1994, Leukemia.

Efficacy and Safety of Hydroxychloroquine Sulphate In Chronic Lymphocytic Leukemia: Clinical Trial Experience In Untreated Patients

N. Chiorazzi, K. Rai, J. Kolitz, 2010 .